InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Facebook feels users’ wrath over Instagram terms of service

Eileen McDermott, New York


Facebook’s fleeting decision to change Instagram’s terms of service yesterday highlights the fine line in social media between sound business policies and PR nightmares

"Legally, the scope of the rights that a company has in user and/or user-generated content depends on the grant of rights provisions in its Terms of Service," said Michael Kasdan of Amster Rothstein & Ebenstein. This means that companies must spell out clearly what their rights are for users in order to guarantee maximum monetisation of the site’s content.

Under Facebook’s proposed model...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

@CubismLaw Thanks. Do you have the agenda? Might be able to attend some but not all of the day!

Jun 30 2015 10:28 ·  reply ·  retweet ·  favourite
ManagingIP profile

Trademark practitioners (and others): Do consider completing this. It's v short and you can win a bottle of fizz! https://t.co/yufEF9u5Bs

Jun 30 2015 08:33 ·  reply ·  retweet ·  favourite
ManagingIP profile

What's holding back China's movie industry? Blog post by Ellen Szymanski of @globalIPcenter http://t.co/Hu7x8Q0Yp0 http://t.co/l4XR3wBCL5

Jun 30 2015 08:30 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements